Table 1. Characteristics of recipients with hepatocellular carcinoma.

Characteristic	Recipients with hepatocellular carcinoma (n=139)
Pretransplant factors
Gender (male/female)	107/32
Model for end-stage liver disease score [range]	13 [2–34]
Child-Pugh score [range]	9 [5–14]
Child-Pugh classification [%]
Child A	10 [7]
Child B	65 [47]
Child C	64 [46]
Diseases [%]
HBV	40 [29]
HCV	84 [60]
HBV, HCV co-infection	2 [1]
Alcohol	5 [4]
Other	8 [6]
Biological marker [range]
Alpha-fetoprotein (ng/mL)	241 [1–11,999]
Des-gamma-carboxy prothrombin (mAU/mL)	290 [60–13,248]
Carcinoembryonic antigen (ng/mL)	6 [1.2–17.0]
Pretransplant treatments [%]
Transcatheter arterial chemoembolization	64 [46]
Radiofrequency ablation	27 [16]
Percutaneous ethanol injection therapy	21 [15]
Liver resection	13 [10]
Chemoembolization	2 [2]
Proton therapy	1 [1]
Tumor number (pretransplant) [range]	1.9 [0–14]
Tumor size (pretransplant) [range] (cm)	2.2 [0–8]
Within Milan criteria (pretransplant) [%]	117 [84]
Within Tokyo criteria (pretransplant) [%]	117 [84]
Tumor number (explants) [range]	3 [0–19]
Tumor size (cm) (explants) [range]	2.0 [0.5–11.0]
Differentiation [%]
Well differentiated	67 [48]
Moderately differentiated	55 [40]
Poorly differentiated	17 [12]
Intraoperative factors [range]
Operation time (min)	897 [604–1,890]
Total blood loss (mL)	7,403 [568–53,853]
Graft volume (g)	571 [361–880]
Graft volume ratio to standard liver volume (%)	47 [31–68]

HBV, hepatitis B virus; HCV, hepatitis C virus.